Lambert-Eaton myasthenic syndrome

Udaya Seneviratne, Rajith De Silva

Research output: Contribution to journalArticleOtherpeer-review

25 Citations (Scopus)

Abstract

The Lambert-Eaton myasthenic syndrome is a neuromuscular disorder characterised by defective neurotransmitter release at autonomic neurones and presynaptic terminals of the neuromuscular junction. It is caused by an IgG autoantibody formed against especially the P/Q type of voltage-gated calcium channels (VGCC) which is an essential component of the mechanism of neurotransmitter release. Many patients have an associated small cell carcinoma of the lung which appears to provide the antigenic stimulus for antibody production, although there is another group with no underlying malignancy. Both groups show an association with immunological disorders. Assay of VGCC antibody titres and electrophysiological tests help to differentiate Lambert-Eaton myasthenic syndrome from other disorders of the neuromuscular junction. Several drugs and therapeutic interventions capable of producing significant clinical improvement are currently available. Patients should also be investigated for underlying tumours, the specific treatment of which can result in remission or amelioration of symptoms.

Original languageEnglish
Pages (from-to)516-520
Number of pages5
JournalPostgraduate Medical Journal
Volume75
Issue number887
Publication statusPublished - Sep 1999
Externally publishedYes

Keywords

  • Lambert-Eaton myasthenic syndrome
  • Voltage-gated calcium channels

Cite this